DFFN - Diffusion Pharmaceuticals Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4652
-0.0048 (-1.02%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.4700
Open0.5000
Bid0.0000 x 1400
Ask0.0000 x 4000
Day's Range0.4105 - 0.5000
52 Week Range0.2100 - 11.0000
Volume3420704
Avg. Volume2,215,319
Market Cap4.6M
Beta (3Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)-3.5300
Earnings DateAug. 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • GlobeNewswire

    Diffusion Pharmaceuticals Presents Early Findings Showing Increased Survival in Lead-in Portion of Phase 3 Glioblastoma Study with TSC plus Standard of Care

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, announces increased survival in inoperable glioblastoma patients enrolled in the 19-patient, open-label, dose-escalation lead-in portion of its Phase 3 study with Trans Sodium Crocetinate (TSC) plus standard of care (SOC). John Gainer, Ph.D., the Company’s chief scientific officer, will present details of these findings at the inaugural Glioblastoma Drug Development Summit being held in Boston December 10-11, and sponsored by Hanson Wade. Dr. Gainer’s slide presentation will be posted to the Company’s website at www.diffusionpharma.com immediately prior to the conference.

  • GlobeNewswire

    Diffusion Pharmaceuticals Announces Closing of $4.0 Million Public Offering

    CHARLOTTESVILLE, Va., Nov. 15, 2019 -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) a clinical-stage biotechnology company.

  • GlobeNewswire

    Diffusion Pharmaceuticals Announces $4.0 Million Public Offering

    Diffusion Pharmaceuticals Inc. (DFFN) (“Diffusion” or the “Company”), a clinical-stage biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced that it has priced a public offering of an aggregate of 11,428,572 shares of common stock (or common stock equivalents) of the Company, together with accompanying common warrants, at a public offering price of $0.35 per share and associated warrants. Each share of common stock (or common stock equivalent) sold in the offering was sold collectively with (i) a common warrant to purchase one share of common stock expiring eighteen months from the date of issuance and (ii) a common warrant to purchase one share of common stock expiring five years from the date of issuance.

  • GlobeNewswire

    Diffusion Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

    Commenced Patient Enrollment in Phase 2 On-Ambulance TSC Clinical Trial for the Treatment of Stroke Reported Favorable Safety Data in Glioblastoma Multiforme Phase 3 Run-in.

  • GlobeNewswire

    First Patient Enrolled in Diffusion Pharmaceuticals’ Phase 2 On-Ambulance Clinical Trial with TSC for the Treatment of Stroke

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, announces that the first patient has been enrolled in its Phase 2 on-ambulance study evaluating trans sodium crocetinate (TSC) for the treatment of stroke.  The 160-patient trial, named PHAST-TSC (Pre-Hospital Administration of Stroke Therapy-TSC), will involve 23 hospitals, working closely with approximately 150 emergency medical transport groups across Central Virginia and urban, suburban and rural areas in Los Angeles County. Diffusion expects enrollment at the University of Los Angeles (UCLA) to begin later this quarter, where about 20 hospital sites will be participating.

  • Will Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Need To Raise More Money?
    Simply Wall St.

    Will Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Need To Raise More Money?

    Trailing twelve-month data shows us that Diffusion Pharmaceuticals Inc.'s (NASDAQ:DFFN) earnings loss has accumulated...

  • GlobeNewswire

    Diffusion Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced that management will present at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 4:40 p.m. Eastern Time. The conference will be held September 8-10 at the Lotte New York Palace Hotel in New York City. To listen to the presentation live, investors may visit the Investor Relations section of Diffusion Pharmaceuticals’ website at www.diffusionpharma.com.

  • GlobeNewswire

    Diffusion Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update

    Company Completes $6.28 Million Registered Direct OfferingFavorable Data Reported in Glioblastoma Multiforme Phase 3 Run-in StudyPhase 2 On-Ambulance TSC Clinical Trial for the.

  • GlobeNewswire

    Diffusion Pharmaceuticals Reports Favorable Safety Data for Dose-Escalation Run-in of Phase 3 INTACT Study in Glioblastoma Multiforme Patients

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions, today reported that based on favorable safety data in a 19-patient dose-escalation run-in study, the Data Safety Monitoring Board (DSMB) has recommended the continuation of the Company’s Phase 3 clinical trial with trans sodium crocetinate (TSC) in inoperable glioblastoma multiforme (GBM) patients. In addition, the DSMB has recommended that the highest dose administered, 1.5 mg/kg of TSC, be used during the adjuvant treatment period of the Phase 3 INTACT trial.

  • The Diffusion Pharmaceuticals (NASDAQ:DFFN) Share Price Is Down 98% So Some Shareholders Are Very Salty
    Simply Wall St.

    The Diffusion Pharmaceuticals (NASDAQ:DFFN) Share Price Is Down 98% So Some Shareholders Are Very Salty

    It's not possible to invest over long periods without making some bad investments. But really bad investments should...

  • GlobeNewswire

    Diffusion Pharmaceuticals Inc. Announces Closing of $6.45 Million Offering Priced At-the-Market

    Diffusion Pharmaceuticals Inc. (DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced the closing of its previously announced registered direct offering, priced at-the-market, with certain institutional investors of 1,317,060 shares of the Company’s common stock, at a price of $4.77 per share, for aggregate gross proceeds of approximately $6.28 million. The Company also issued 1,317,060 unregistered warrants to the institutional investors in a concurrent private placement to purchase one share of common stock for each share of common stock purchased with an exercise price of $5.00 per share for aggregate gross proceeds of approximately $165 thousand.

  • GlobeNewswire

    Diffusion Pharmaceuticals Inc. Announces $6.45 Million Registered Direct Offering & Private Placement

    Diffusion Pharmaceuticals Inc. (DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced that it has entered into a definitive securities purchase agreement with certain institutional investors to purchase in a registered direct offering 1,317,060 shares of the Company’s common stock, at a price of $4.77 per share, for aggregate gross proceeds of approximately $6.28 million. The Company also agreed to issue 1,317,060 unregistered warrants to the institutional investors in a concurrent private placement to purchase one share of common stock for each share of common stock purchased with an exercise price of $5.00 per share for aggregate gross proceeds of approximately $165 thousand.

  • GlobeNewswire

    Diffusion Pharmaceuticals Receives Notice of Intention to Grant a Patent Related to Use of TSC in Combination with tPA in Ischemic Stroke from European Patent Office

    Diffusion Pharmaceuticals Inc. (DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced receipt from the European Patent Office of a Notice of Intention to Grant a patent related to the use of the Company’s lead compound trans sodium crocetinate (“TSC”) in combination with the leading thrombolytic, tissue plasminogen activator (“tPA”), in the treatment of ischemic stroke. The patent claim covers administration of TSC within three or four hours of the onset of stroke symptoms in combination with tPA administered within nine to 12 hours of the onset of stroke symptoms.

  • GlobeNewswire

    Diffusion Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

    CHARLOTTESVILLE, Va., May 09, 2019 -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical.

  • GlobeNewswire

    Diffusion Pharmaceuticals Reports 2018 Financial Results and Provides Business Update

    CHARLOTTESVILLE, Va., March 20, 2019 -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening.

  • GlobeNewswire

    Poster Presented at International Stroke Conference Describing Diffusion’s On-Ambulance Phase 2 Trial with TSC for Treating Acute Stroke

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, today announced the presentation of a poster detailing an innovative on-ambulance Phase 2 study with the Company’s lead drug trans sodium crocetinate (TSC) for the treatment of acute stroke. The poster was presented on February 7th at the American Heart Association’s International Stroke Conference, held February 6-8 in Honolulu.

  • How Does Investing In Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Impact The Volatility Of Your Portfolio?
    Simply Wall St.

    How Does Investing In Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Impact The Volatility Of Your Portfolio?

    If you own shares in Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • GlobeNewswire

    Diffusion Pharmaceuticals Chief Executive Officer David Kalergis to Present at 37th Annual J.P. Morgan Healthcare Conference

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced today that Chief Executive Officer David Kalergis will join investors, executives, civic leaders, and scientists to present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 7:00pm EST/4:00pm PST. The Conference will be held on January 7-10, 2019 at the Westin St. Francis Hotel in San Francisco, California.

  • GlobeNewswire

    Diffusion Pharmaceuticals Executes Successful NASDAQ Compliance Plan: Company Will Remain Listed on NASDAQ Stock Market

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, today announced it received notice from NASDAQ staff that the Company has regained compliance with Listing Rule 5550(a)(2) and will remain listed on the NASDAQ stock market. The news came as a result of the closing bid price of Diffusion’s stock remaining above $1.00 per share between December 14 and December 28, 2018. This latest news follows a number of exciting recent developments, including FDA approval of a Phase 2 on-ambulance clinical trial for the treatment of stroke using the Company’s lead drug, Trans Sodium Crocetinate (TSC) and the U.S. Patent Office awarding the Company a patent for the use of TSC in conjunction with Tissue Plasminogen Activator (tPA), which remains the only FDA-approved therapeutic stroke treatment.

  • ACCESSWIRE

    Today's Research Reports on Trending Tickers: Evofem Biosciences and Diffusion Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 18, 2018 / Evofem Biosciences had a day of gains on Monday after announcing positive results on its hormone free birth control gel. Shares of Diffusion Pharmaceuticals were in the red despite announcing that the company was awarded a patent for the use of its breakthrough drug, trans sodium crocetinate (TSC), in conjunction with Tissue Plasminogen Activator (tPA) for the treatment of stroke.

  • ACCESSWIRE

    4 Stocks Providing Investor Opportunity Right Now

    On Monday 12/17/2018, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI), Diffusion Pharmaceuticals Inc. (DFFN), Evofem Biosciences, Inc. (EVFM) and Synergy Pharmaceuticals Inc. (SGYP) are presenting investors with upside opportunity ahead of Christmas and the 2019 New Year. Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) a company you may have not heard of yet, has seen a strong month of bullish trading and shares of the company have climbed by as much as 31% over the last 30 days. The Company has been focusing on a growth strategy with key announcements which continue to build new interest.

  • GlobeNewswire

    U.S. Patent Office Awards Diffusion Exclusive Rights for Use of TSC in Conjunction with Only FDA-Approved Stroke Therapeutic

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced today that it has been awarded a patent for the use of its breakthrough drug, trans sodium crocetinate (TSC), in conjunction with Tissue Plasminogen Activator (tPA) for the treatment of stroke. Currently, tPA – a thrombolytic used to break down blood clots in patients suffering from ischemic stroke – is the only FDA-approved therapeutic stroke treatment.

  • GlobeNewswire

    Diffusion Pharmaceuticals Announces 1-for-15 Reverse Stock Split As Part Of NASDAQ Compliance Plan

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-15, effective for trading purposes prior to the opening of the market on December 14, 2018. The Company’s ticker symbol, DFFN, will remain unchanged. The new CUSIP number for Diffusion’s post-reverse split common stock will be 253748 305.